| P50 | author | Joshua C. Denny | Q56425939 |
| | Hua Xu | Q86966653 |
| | Hongfang Liu | Q88683053 |
| P2093 | author name string | Jun Xu | |
| | Ping Yang | |
| | Min Jiang | |
| | Liwei Wang | |
| | Qingxia Chen | |
| | Hui Nian | |
| | Yonghui Wu | |
| | Qi Dai | |
| | Jeremy L Warner | |
| | Xianglin Du | |
| P2860 | cites work | Predicting new molecular targets for known drugs | Q24649687 |
| | Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality | Q24745996 |
| | Rapalogs and mTOR inhibitors as anti-aging therapeutics | Q28286510 |
| | Systematic drug repositioning based on clinical side-effects | Q28478506 |
| | Construction of drug network based on side effects and its application for drug repositioning | Q28539501 |
| | Evaluating temporal relations in clinical text: 2012 i2b2 Challenge | Q28681390 |
| | Metformin and reduced risk of cancer in diabetic patients | Q29616275 |
| | Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16 | Q33602223 |
| | PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations | Q33808357 |
| | Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets | Q33903831 |
| | A phenome-guided drug repositioning through a latent variable model | Q34062615 |
| | MedEx: a medication information extraction system for clinical narratives. | Q34371568 |
| | The effect of calcium channel blockers on the outcome of acute myeloid leukemia | Q34422254 |
| | Statin use and reduced cancer-related mortality | Q34645107 |
| | Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival | Q35688186 |
| | Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership | Q35927074 |
| | Chemopreventive action of non-steroidal anti-inflammatory drugs on the inflammatory pathways in colon cancer | Q35929687 |
| | Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas | Q35981176 |
| | Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study | Q36285977 |
| | Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. | Q36532994 |
| | Extracting genetic alteration information for personalized cancer therapy from ClinicalTrials.gov | Q37051425 |
| | Development of a large-scale de-identified DNA biobank to enable personalized medicine. | Q37149522 |
| | Multilayered temporal modeling for the clinical domain | Q37229228 |
| | A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation | Q37246506 |
| | Antihypertensive drugs and lip cancer in non-Hispanic whites | Q37257528 |
| | Reengineering translational science: the time is right | Q37403328 |
| | Literature mining, ontologies and information visualization for drug repurposing | Q37895399 |
| | The year's new drugs & biologics, 2013: Part I. | Q38187669 |
| | Systematic drug repurposing through text mining | Q38208688 |
| | Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma. | Q38724921 |
| | Increased survival rate by local release of diclofenac in a murine model of recurrent oral carcinoma | Q38735678 |
| | Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. | Q38857937 |
| | Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval | Q39431314 |
| | Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. | Q39944738 |
| | The $2.6 billion pill--methodologic and policy considerations | Q40944246 |
| | Statin use and survival from lung cancer: a population-based cohort study. | Q40985401 |
| | Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease | Q41777292 |
| | The emergence of genome-based drug repositioning | Q42080559 |
| | Association between captopril, other antihypertensive drugs and risk of prostate cancer | Q42615481 |
| | Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study | Q44086372 |
| | Statin use after colorectal cancer diagnosis and survival: a population-based cohort study | Q44166795 |
| | Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. | Q44308840 |
| | Patients in context--EHR capture of social and behavioral determinants of health | Q44457645 |
| | Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. | Q46236774 |
| | Mining small-molecule screens to repurpose drugs. | Q47583144 |
| | e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design. | Q47993030 |
| | IDMap: facilitating the detection of potential leads with therapeutic targets. | Q51888340 |
| | Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). | Q53476716 |
| | Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer | Q79643576 |
| | The cost of new drug discovery and development | Q84730346 |
| | Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery | Q87166810 |
| | To all involved - we have a problem | Q89032187 |
| P921 | main subject | electronic health records | Q10871684 |
| P304 | page(s) | 1-9 | |
| P577 | publication date | 2019-05-01 | |
| P1433 | published in | JCO Clinical Cancer Informatics | Q85770379 |
| P1476 | title | Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing | |
| P478 | volume | 3 | |